Ea. Walker et al., BUPRENORPHINE ANTAGONISM OF MU-OPIOIDS IN THE RHESUS-MONKEY TAIL-WITHDRAWAL PROCEDURE, The Journal of pharmacology and experimental therapeutics, 273(3), 1995, pp. 1345-1352
The apparent in vivo dissociation constant (K-A) and relative efficacy
values for alfentanil, etonitazene, morphine, and nalbuphine were det
ermined by comparing the effects of these agonists in the presence of
buprenorphine with the effects of these agonists alone in the rhesus m
onkey tail-withdrawal procedure. Initial time course studies of bupren
orphine alone indicated that 3.2 and 10 mg/kg produced increases in ta
il-withdrawal latencies when studied with 48 degrees C water for 48 hr
. No increases in tail-withdrawal latency were found with either dose
studied with 55 degrees C water. Buprenorphine produced dose-dependent
shifts to the right for the antinociceptive effects of alfentanil, et
onitazene, morphine and nalbuphine 72 hr after administration and decr
eased the maximal effects of morphine in 48 degrees C water and those
of alfentanil and etonitazene in 55 degrees C water. Buprenorphine adm
inistration decreased the receptors available for agonist interaction
to approximately 2%. The average apparent in vivo dissociation constan
t (K-A) values for alfentanil, etonitazene, morphine and nalbuphine we
re 3.3, 0.073, 60 and 31 mg/kg, respectively. High efficacy estimates
were determined for alfentanil (149-203) and etonitazene (174-203), wh
ereas lower efficacy estimates were determined for nalbuphine (57) and
morphine (17). The apparent in vivo dissociation constant of a pseudo
irreversible antagonist (K-B) value for buprenorphine averaged 0.15 mg
/kg across agonists, temperatures and buprenorphine doses. These data
extend and emphasize the significance of in vivo estimates of affinity
and relative efficacy for drug classification.